semaglutide and prolactinoma – My Endo Consult Clinical consequences of prolactinoma include

Data suggest that semaglutide may lower the 10-year risk of developing type 2 diabetes by as much as 60% in people with overweight and weight-related complications or with obesity while on treatment

This landmark study evaluated the efficacy and safety of ustekinumab, an interleukin-12 and interleukin-23 antagonist, in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis

A few small human studies suggest possible skin benefits, but sample sizes were modest and long-term safety data are absent

So this isn't something that kicks in overnight it's a gradual escalation designed to let the body adjust.What About People Already on the Injection?Here's where it gets particularly practical